Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors
† Institute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Albertstraße 25, 79104 Freiburg, Germany
‡ Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Straße 4, 06120 Halle (Saale), Germany
§ Département de Biologie Structurale Intégrative, Institut de Génétique et Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UDS), CNRS, INSERM, 1 Rue Laurent Fries, 67404 Illkirch Cedex, France
∥ Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
J. Med. Chem., 2016, 59 (4), pp 1545–1555
DOI: 10.1021/acs.jmedchem.5b01493
Publication Date (Web): December 10, 2015
Copyright © 2015 American Chemical Society
*Phone: +497612034896. E-mail: manfred.jung@pharmazie.uni-freiburg.de.
This article is part of the Epigenetics special issue.
Abstract
Histone deacetylase 6 (HDAC6) catalyzes the removal of an acetyl group from lysine residues of several non-histone proteins. Here we report the preparation of thiazole-, oxazole-, and oxadiazole-containing biarylhydroxamic acids by a short synthetic procedure. We identified them as selective HDAC6 inhibitors by investigating the inhibition of recombinant HDAC enzymes and the protein acetylation in cells by Western blotting (tubulin vs histone acetylation). The most active compounds exhibited nanomolar potency and high selectivity for HDAC6. For example, an oxazole hydroxamate inhibits HDAC6 with an IC50 of 59 nM and has a selectivity index of >200 against HDAC1 and HDAC8. This is the first report showing that the nature of a heterocycle directly connected to a zinc binding group (ZBG) can be used to modulate subtype selectivity and potency for HDAC6 inhibitors to such an extent. We rationalize the high potency and selectivity of the oxazoles by molecular modeling and docking.
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.5b01493.
- Additional experimental details and spectral data for the compounds; Western blots with BE(2)-C cells; 1H and 13C NMR spectra of compound 4g (PDF)
- Molecular formula strings (CSV)
Citation data is made available by participants in CrossRef's Cited-by Linking service. For a more comprehensive list of citations to this article, users are encouraged to perform a search in SciFinder.
- Zhi-You Huang
, Jing-Fang Yang, Ke Song, Qian Chen, Shao-Lin Zhou, Ge-Fei Hao, and Guang-Fu YangThe Journal of Organic Chemistry 2016 81 (20), 9647-9657 Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137)
Claudia A. Simões-Pires, Philippe Bertrand, Muriel CuendetExpert Opinion on Therapeutic Patents 2017 27 (3), 229-236Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold
Rob De Vreese, Lisa Galle, Yves Depetter, Jorick Franceus, Tom Desmet, Kristof Van Hecke, Veronick Benoy, Ludo Van Den Bosch, Matthias D'hoogheChemistry - A European Journal 2017 23 (1), 128-136Selective histone deacetylase small molecule inhibitors: recent progress and perspectives
Hai-Tao Qin, Huan-Qiu Li, Feng LiuExpert Opinion on Therapeutic Patents 2016 , 1-15A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors
Laura Goracci, Nathalie Deschamps, Giuseppe Marco Randazzo, Charlotte Petit, Carolina Dos Santos Passos, Pierre-Alain Carrupt, Claudia Simões-Pires, Alessandra NurissoScientific Reports 2016 6 (1),
http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b01493
Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors
Abstract
Histone deacetylase 6 (HDAC6) catalyzes the removal of an acetyl group from lysine residues of several non-histone proteins.
Here we report the preparation of thiazole-, oxazole-, and oxadiazole-containing biarylhydroxamic acids by a short synthetic procedure.
We identified them as selective HDAC6 inhibitors by investigating the inhibition of recombinant HDAC enzymes and the protein acetylation in cells by Western blotting (tubulin vs histone acetylation).
The most active compounds exhibited nanomolar potency and high selectivity for HDAC6. For example, an oxazole hydroxamate inhibits HDAC6 with an IC50 of 59 nM and has a selectivity index of >200 against HDAC1 and HDAC8.
This is the first report showing that the nature of a heterocycle directly connected to a zinc binding group (ZBG) can be used to modulate subtype selectivity and potency for HDAC6 inhibitors to such an extent. We rationalize the high potency and selectivity of the oxazoles by molecular modeling and docking.
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.5b01493.
- Additional experimental details and spectral data for the compounds; Western blots with BE(2)-C cells; 1H and 13C NMR spectra of compound 4g (PDF)
- Molecular formula strings (CSV)
0 件のコメント:
コメントを投稿